These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 31811553)

  • 1. Immunotherapy in pediatric acute lymphoblastic leukemia.
    Inaba H; Pui CH
    Cancer Metastasis Rev; 2019 Dec; 38(4):595-610. PubMed ID: 31811553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the treatment of acute lymphoblastic leukemia.
    Rafei H; Kantarjian HM; Jabbour EJ
    Leuk Lymphoma; 2019 Nov; 60(11):2606-2621. PubMed ID: 31092071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOHO State of the Art Update and Next Questions: Advances in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Paul S; Rausch CR; Welch MA; Kantarjian HM; Jabbour EJ
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):471-479. PubMed ID: 31307896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies in acute lymphoblastic leukemia therapy.
    Chitadze G; Laqua A; Lettau M; Baldus CD; Brüggemann M
    Expert Rev Hematol; 2020 Nov; 13(11):1211-1233. PubMed ID: 33000968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Therapies in the Treatment of Adult Acute Lymphoblastic Leukemia.
    Gavralidis A; Brunner AM
    Curr Hematol Malig Rep; 2020 Aug; 15(4):294-304. PubMed ID: 32445026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.
    Horvat TZ; Seddon AN; Ogunniyi A; King AC; Buie LW; Daley RJ
    Ann Pharmacother; 2018 Mar; 52(3):268-276. PubMed ID: 29025266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
    Jabbour E; Sasaki K; Ravandi F; Huang X; Short NJ; Khouri M; Kebriaei P; Burger J; Khoury J; Jorgensen J; Jain N; Konopleva M; Garcia-Manero G; Kadia T; Cortes J; Jacob J; Montalbano K; Garris R; O'Brien S; Kantarjian HM
    Cancer; 2018 Oct; 124(20):4044-4055. PubMed ID: 30307611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia.
    Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A
    Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel antibody therapy in acute lymphoblastic leukemia.
    Kochuparambil ST; Litzow MR
    Curr Hematol Malig Rep; 2014 Jun; 9(2):165-73. PubMed ID: 24623281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should immunologic strategies be incorporated into frontline ALL therapy?
    Rank CU; Stock W
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):367-372. PubMed ID: 30466749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status of cancer immunotherapy for relapsed/refractory acute lymphoblastic leukemia in children and adolescents in Japan].
    Imai C
    Rinsho Ketsueki; 2020; 61(6):673-681. PubMed ID: 32624542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody based therapy in relapsed acute lymphoblastic leukemia.
    Jammal N; Chew S; Jabbour E; Kantarjian H
    Best Pract Res Clin Haematol; 2020 Dec; 33(4):101225. PubMed ID: 33279181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of Response to FDA-Approved Targeted Therapy and Immunotherapy in Acute Lymphoblastic Leukemia (ALL).
    Khawaji ZY; Khawaji NY; Alahmadi MA; Elmoneim AA
    Curr Treat Options Oncol; 2024 Sep; 25(9):1163-1183. PubMed ID: 39102166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment.
    Gupta S; Maude SL; O'Brien MM; Rau RE; McNeer JL
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S8-S11. PubMed ID: 32862880
    [No Abstract]   [Full Text] [Related]  

  • 15. Switching from salvage chemotherapy to immunotherapy in adult B-cell acute lymphoblastic leukemia.
    Kegyes D; Jitaru C; Ghiaur G; Ciurea S; Hoelzer D; Tomuleasa C; Gale RP
    Blood Rev; 2023 May; 59():101042. PubMed ID: 36732205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of relapsed/refractory acute lymphoblastic leukemia.
    Paul S; Rausch CR; Nasnas PE; Kantarjian H; Jabbour EJ
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):166-175. PubMed ID: 30969955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
    Rubinstein JD; Breese EH; Krupski MC; O'Brien MM; Dandoy CE; Mizukawa B; Khoury R; Norris RE; Davies SM; Phillips CL
    Transplant Cell Ther; 2023 May; 29(5):311.e1-311.e7. PubMed ID: 36809824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of KTE-X19 for Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in the United States.
    Shah BD; Smith NJ; Feng C; Jeyakumar S; Castaigne JG; Faghmous I; Masouleh BK; Malone DC; Bishop MR
    Adv Ther; 2022 Aug; 39(8):3678-3695. PubMed ID: 35727476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysis.
    Jabbour EJ; Sasaki K; Ravandi F; Short NJ; Garcia-Manero G; Daver N; Kadia T; Konopleva M; Jain N; Cortes J; Issa GC; Jacob J; Kwari M; Thompson P; Garris R; Pemmaraju N; Yilmaz M; O'Brien SM; Kantarjian HM
    Cancer; 2019 Aug; 125(15):2579-2586. PubMed ID: 30985931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.